Creative Medical Extends Breakout as Patent Momentum Fuels Continued Buying InterestCreative Medical (NASDAQ:CELZ) is continuing to attract investor attention after building on yesterday's patent-driven rally, with shares reaching an intraday high of $1.94 as momentum carried into a second trading session. The latest move follows news that the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering the company's exosome-based immunotherapy platform targeting Type 1 diabetes, further strengthening its growing intellectual property portfolio.